Vistagen therapeutics reports fiscal 2021 third quarter financial results and provides update on expected clinical studies in calendar 2021

Multiple clinical studies anticipated to launch in calendar 2021, notably pivotal phase 3 clinical studies of ph94b as a potential acute treatment of anxiety in adults with social anxiety disorder (sad)
VTGN Ratings Summary
VTGN Quant Ranking